Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis

• Published in: The Prostate 2010-02, Vol.70 (2), p.155-161
• Main Authors: Isahaya, Etsuko, Hara, Noboru, Nishiyama, Tsutomu, Hoshii, Tatsuhiko, Takizawa, Itsuhiro, Takahashi, Kota
• Format: Article
• Language: English
• Subjects: Aged; Androgen Antagonists - adverse effects; androgen deprivation therapy; Antineoplastic Agents, Hormonal - therapeutic use; Bone Density; Bone Diseases, Metabolic - blood; Bone Diseases, Metabolic - etiology; Bone Diseases, Metabolic - metabolism; Bone Diseases, Metabolic - urine; bone metabolism; Flutamide - therapeutic use; Goserelin - therapeutic use; Human Growth Hormone - analysis; Humans; Insulin-Like Growth Factor I - analysis; insulin-like growth factor-1; Male; Middle Aged; Orchiectomy - adverse effects; Parathyroid Hormone - analysis; Prospective Studies; Prostatic Neoplasms - blood; Prostatic Neoplasms - therapy; Prostatic Neoplasms - urine
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.21047

BACKGROUND Although androgen deprivation therapy (ADT) has been associated with bone loss in patients with prostate cancer, its mechanism remains unclear. The growth hormone (GH)/insulin‐like growth factor‐1 (IGF‐1)/parathyroid hormone (PTH) axis plays a critical role in bone synthesis, but its activity during ADT is also unknown. METHODS Seventy‐one patients with localized prostate cancer, who received ADT, were prospectively studied based on their bone mineral density (BMD) and blood and urine samples at the baseline and after ADT for 6 months. RESULTS The IGF‐1 level was correlated with BMD before ADT (rs = 0.325, P = 0.007), but such a relationship disappeared after ADT (P = 0.565). Following ADT, the serum IGF‐1 level increased compared with that at the baseline (22 ± 6 nmol/L vs. 19 ± 5 nmol/L, respectively, P